Sanofi India Ltd - 500674 - Investor Awareness On Online Dispute Resolution Mechanism
Investor awareness on Online Dispute Resolution Mechanism23-09-2023
23-09-2023
Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor / Analysts Meet21-09-2023
Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Change in Management
Change in Senior Management14-09-2023
Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant Reg 39(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that company has approved issue of duplicate share certificates request in lieu of the original share certificates reported lost/misplaced.22-08-2023
Sanofi India Ltd - 500674 - Announcement Under Regulation 30 - Pending Litigation
Pursuant to Regulation 30 read with schedule III - Para B of Part A of the SEBI Listing Regulations and SEBI Circular bearing Ref. No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 the details of ongoing litigations which meets materiality thresholds as prescribed under the SEBI Listing Regulations are enclosed as Annexure-I.14-08-2023
Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find the enclosed copies of the Newspaper publication of Financial Results for quarter and six months ended 30th June 2023 of the company published on 12th August 2023 in Business Standard(English) and Sakal (Marathi) Newspapers.14-08-2023
Q2CY23 Quarterly Result Announced for Sanofi India Ltd.
Pharmaceuticals company Sanofi India announced Q2CY23 results: The company has delivered revenue growth of 2% for Q2CY23 on a comparable basis and 12% growth in operating profits, despite the negative impact of the revised pricing for products listed in the National List of Essential Medicines. Exports for Q2CY23 grew by 30% as compared to Q2CY22. The profit from operations for Q2CY23 was at Rs 168 crore versus Rs 150 crore in Q2CY22, i.e., a growth of 12% while the operating margins increased from 21.5% in Q2CY22 to 23.7% in Q2CY23. The improved operating margins were a result of the Company’s focus mainly on lowering expenses through overall operating efficiencies. The company continues to make good progress on its ‘India for India’ strategy through go-to-market initiatives, improving operating efficiency, and promoting innovation. Managing Director, Sanofi India, said, “The Company has delivered a strong second quarter performance despite the NLEM impact. The Company’s ‘India for India’ strategy reflects Sanofi’s ambition in the Indian Market. The Company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its established and innovative products in India.” Result PDF11-08-2023
Sanofi India Ltd - 500674 - Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended 30Th June 2023
Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th June 202310-08-2023
Sanofi India Ltd - 500674 - Board Meeting Outcome for Board Meeting Outcome
Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we enclose a copy of Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th June 2023 approved at this meeting along with a copy of Limited Review Report. Also enclosed is a copy of Press Release issued in this regard.10-08-2023
Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Change in Management
Pursuant to Reg. 30 of the SEBI Listing Regulations, we wish to inform you that Mr. Gaurav Bahadur, People India Director, resigned from the Company with effect from the close of business hours on 1st August 2023, to pursue other opportunities outside Sanofi. Kindly refer to the enclosed disclosure for further details.03-08-2023